Anavex Life Sciences Corp (AVXL)

[falconer66a]

First is best? Uh?

...there are plenty of competitors out there pushing hard to to get their drugs to market first.

Well, of course there are. But, please tell; how might that matter to Anavex? Are there any regulations limiting the number of drugs that can be approved to treat CNS diseases? If some drug (such as blarcamesine) produces more favorable therapeutic outcomes after other drugs have been on the market, is it disqualified; got in too late to be approved?

How did being first work for Aduhelm and Biogen? Oops. They were second, after Aricept. So, there’s no room now for any new Alzheimer’s drugs? Physicians, pharmacists, and patients will surely want to stay with those who got to market first. It’s the only thing that counts? Right?

Or....